Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging due to its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
Fleming Europe invites you to
Orphan Drug Congress 2011. We have gathered worldwide Pharma specialists who will share their knowledge with you. Hear them speak about
regulatory landscape for orphan drug development, discuss
how to overcome challenges of orphan drug development and commercialization and examine marketing authorization challenges. Come and listen to real life case studies, discover innovative approaches and benefit from interactive discussions with your peers to benchmark your experiences.
At this conference, you will have the
chance to meet true market leaders, top speakers and real experts from pharmaceutical industry. Do not miss the opportunity to gain new knowledge and join us at this event of the year.
For speaking and panelist opportunities please contact:
Alexandra Stanakova, Conference Producer
alexandra.stanakova@flemingeurope.com
T: +421 257 272 121
F: +421 255 644 490
For sponsorship opportunities please contact:
Paul Clark
paul.clark@flemingeurope.com
T: +36 1 411 1840
F: +36 1 411 1841
Key speakers: - VP, Head of the Orphan and Genetic Diseases Research Unit, Pfizer, USA
- Executive Chairman, Swedish Orphan Biovitrum, Switzerland
- Vice President Access to Medicines, Sanofi Aventis, France
- CEO, HRA Pharma, France
- Founder & President, OrphaNet, France
- Vice President South European Region, Celgene, Spain
- Professor of Medical Oncology in the University of Edinburgh Medical School, Member of the board Pharma MAR, Chairman of the Advisory Group on Oncology, Commission on Human Medicines
- Vice President, Translational Sciences, Ipsen, France, Member of the Research and Innovation Council at ARIIS
Key topics: - How to Manage Best the Development Plan for Orphan Drugs
- Processes of Market Authorization Application within the EU
- Impact of the EU Pediatric Regulation on Orphan Drug Development
- How to build a successful orphan drug business in the real market place
- Latest Developments in Pricing & Reimbursement of Orphan Medicines
Who should attend: From Pharmaceutical Companies:
Presidents, VPs, Directors and Heads/Managers of Orphan Drug Discovery/Development, Therapeutic Development, Marketing & Medical Affairs, Business Unit, Regulatory Affairs, External Affairs, Market Access
From Biotechs:
CEOs, CMOs and CSOs
Together with:
Regulatory Bodies
HTA agencies
Academics
Research centers
